Next Article in Journal
NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection
Previous Article in Journal
Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 8
10.3390/vaccines10081306
Review Report
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Race for Global Equitable Access to COVID-19 Vaccines

Vaccines 2022, 10(8), 1306; https://doi.org/10.3390/vaccines10081306
by Lukman Nul Hakim Md Khairi 1,2, Mathumalar Loganathan Fahrni 1,3,* and Antonio Ivan Lazzarino 4
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Vaccines 2022, 10(8), 1306; https://doi.org/10.3390/vaccines10081306
Submission received: 3 July 2022 / Revised: 5 August 2022 / Accepted: 9 August 2022 / Published: 12 August 2022

Round 1

Reviewer 1 Report

The review by Khairi et al., summarizes the current updates on COVID vaccine development and the global efforts to make the vaccines available for public. The review also talks about the limitations of certain vaccine candidates based on their storage, and dosing requirements, and authors comment on the measures being taken to increase the production, allocation, and deployment of COVID vaccines. 

I have the following comments- 

1. I believe that the introduction can be elaborated a bit more. You can comment on the fact that mRNA vaccines for COVID are the first to ever receive FDA approval and the accelerated rate at which this occurred, and how it impacted the pandemic. 

2. Although it is important to ensure that vaccines are accessible to everyone, their safety and efficacy are utmost important. There have been many complications with certain vaccines including both single-dose and multi-dose. Please address this area as well in the review. 

3. Under the Development of single-dose covid vaccines section, please discuss the effectiveness of the current available single-dose vaccines. 

4. Under section 8, please add any effectiveness data available from subjects that received combination vaccines. 

5. Line 50- Please add "to control the spread" next to "consolidated approach". 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

A short presentation of COVID-19 pathology would be welcomed in the Introduction section

Diverse COVID-19 variants should be discussed, efficiency of vaccines against certain subtypes of the virus should be presented

The timeline of vaccine introduction is missing

Table 1 is not formatted according to journal recommendations

Issues regarding reluctance at vaccination is a reality in several countries, however it is not discussed in the article

Regulatory data regarding COVID vaccine introductions should be presented

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop